Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by UBS Group from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, The Fly reports.
Other equities research analysts also recently issued research reports about the company. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 22nd. Oppenheimer cut Enanta Pharmaceuticals from an “outperform” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research report on Wednesday. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $111.00 price objective on the stock in a research report on Thursday, May 3rd. JMP Securities reiterated a “buy” rating and set a $120.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. Finally, Roth Capital assumed coverage on Enanta Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $133.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Enanta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $90.43.
Enanta Pharmaceuticals traded down $3.01, hitting $88.75, during mid-day trading on Wednesday, Marketbeat reports. 8,988 shares of the company’s stock traded hands, compared to its average volume of 311,155. Enanta Pharmaceuticals has a fifty-two week low of $37.13 and a fifty-two week high of $127.77. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of 97.92 and a beta of 0.92.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by ($0.01). Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. The business had revenue of $57.26 million for the quarter, compared to analyst estimates of $56.59 million. sell-side analysts expect that Enanta Pharmaceuticals will post 3.36 EPS for the current year.
In related news, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $105.25, for a total value of $437,313.75. Following the transaction, the vice president now owns 8,955 shares in the company, valued at $942,513.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jay R. Luly sold 25,000 shares of the firm’s stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $105.83, for a total value of $2,645,750.00. Following the completion of the transaction, the insider now owns 638,994 shares in the company, valued at approximately $67,624,735.02. The disclosure for this sale can be found here. Insiders have sold a total of 88,355 shares of company stock worth $10,382,033 in the last quarter. Company insiders own 10.56% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Meadow Creek Investment Management LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth $110,000. SG Americas Securities LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth $112,000. Riverhead Capital Management LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth $129,000. Glen Harbor Capital Management LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth $140,000. Finally, Sei Investments Co. increased its position in shares of Enanta Pharmaceuticals by 63,966.7% in the first quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,919 shares during the period. Institutional investors own 77.01% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Article: Book Value Per Share – BVPS
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.